Thermo Fisher Acquires Henogen S.A.
After a surprise collapse of its takeover bid for QIAGEN N.V. (NYSE: QGEN), Thermo Fisher Scientific Inc. (NYSE: TMO) is back with a new deal in 2021. Thermo Fisher is buying Henogen S.A. from Groupe Novasep SAS for approximately EUR 725 million ($877.5 million) in cash. Based in Belgium, Henogen S.A. is a viral vector manufacturing business that provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers. Groupe Novasep partners with a variety of industries to provide technically optimized and economical solutions for the life science industry. Henogen has two facilities and approximately 400 employees with substantial... Read More »
Butterfly Network Undergoes Reverse Merger
Another week, another reverse merger. Private companies going public through a special purpose acquisition company (SPAC) seem to be a dime a dozen in 2020. Primary Care operator Cano Health, LLC announced it was going public last week in a deal valued at $4.4 billion, and Clover Health struck a $3.7 billion reverse merger with Social Capital Hedosophia Holdings Corp. III (NYSE: IPOC). This time, the SPAC is Longview Acquisition Corp. (NYSE: LGVW), which is sponsored by Glenview Capital Management, LLC. The company going public is Butterfly Network, Inc., which created the world’s first handheld, single-probe whole-body ultrasound system, Butterfly iQ, to make ultrasound technology more... Read More »
Diagnostics, COVID-19 and Beyond
Testing has become one of the most defining words of 2020, especially as it relates to the COVID-19 pandemic. We see it in headlines daily and President Trump lists the testing capacity of the United States as one of his crowning achievements. But politics and media coverage aside, health experts often cite testing as one of the key components to containing the spread of the virus, underscoring the importance of those services. The demand for COVID-19 testing and diagnostics can be seen in recent quarterly earnings reports. LabCorp’s (NYSE: LH) revenue jumped by 33% in Q3:20 to $3.9 billion, compared with Q3:19. Roughly 31.5% of the increase was thanks to organic growth, bolstered by... Read More »
Exact Sciences Acquires Thrive Earlier Detection
After over a year away from the healthcare M&A market, Exact Sciences Corp. (NYSE: EXAS) is back with a new acquisition. Last week, the company announced it purchased Cambridge, Massachusetts-based Thrive Earlier Detection Corp., a healthcare company focused on incorporating earlier cancer detection into routine medical care. Thrive is developing CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of disease. Under the terms of the agreement, Exact Science will pay $1.7 billion at closing, consisting of Exact Sciences common stock and 35% in cash. An additional $450 million would be payable based upon the achievement of certain milestones.... Read More »
Innovative Renal Care Acquires American Renal Associates
Innovative Renal Care, a portfolio company of Nautic Partners, has significantly expanded its network through a new acquisition. The dialysis provider has added American Renal Associates Holdings, Inc. (NYSE: ARA) for $853 million, or $11.50 per share in cash, representing an approximate premium of 66% to the company’s closing price on October 1, 2020. The price includes net debt. ARA is a leading provider of outpatient dialysis services in the United States. As of June 30, 2020, ARA operated 251 dialysis clinic locations in 27 states and the District of Columbia serving more than 17,300 patients with end-stage renal disease. ARA generated 12-month revenues of $815.8 million with EBITDA of... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
